Search Within

Isabelle C Riviere

  1. "Bone Marrow Transplant"
  2. "Adult Leukemia"
  3. "American Society of Hematology"
  4. "Pediatrics, Department of"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (2)
Groups
  1. Adult Leukemia (11)
  2. Bone Marrow Transplant (11)
  3. Center for Hematologic Malignancies (11)
  4. Department of Medicine (11)
  5. GSK Faculty (11)
  6. Hematologic Malignancies Research (11)

More Groups

People
  1. Jae Park (11)
  2. Renier Brentjens (11)
  3. Craig Sauter (10)
  4. Kevin Curran (10)
  5. Xiuyan Wang (9)
  6. Michel Sadelain (8)

More People

Years
  1. 2021 (1)
  2. 2019 (2)
  3. 2018 (1)
  4. 2017 (2)
  5. 2015 (2)
  6. 2014 (3)
Publications
  1. Blood (11)
Publishers
  1. American Society of Hematology (11)

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; RivieĢ€re, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL
    Meeting Abstract

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL
    Meeting Abstract

    Curran, K. J.; Riviere, I.; Silverman, L. B.; Kobos, R.; Shukla, N.; Steinherz, P. G.; Boulad, F.; Prockop, S.; Scaradavou, A.; Margossian, S. P.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y. J.; Wang, X. Y.; Purdon, T. J.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save